Thursday 13th September 2012
|Text too small?|
Tower chairman Bill Falconer has stepped down as the insurer considers proposals from other parties following a strategic review aimed at lifting the value of the company.
Falconer, who was due to retire in February, will be replaced by director Steve Smith as interim chairman in a move that would "enable a new chairman to implement the initiatives emanating from the strategic review," the Wellington-based company said in a statement today.
Tower "is considering a number of proposals with interested parties after completing a strategic review" undertaken by senior managers with the support of Goldman Sachs, it said.
The company's strength "was not reflected in the market price for Tower shares at a time when the company had achieved strong financial results and had strengthened operational efficiency," said managing director Rob Flannagan.
"While Tower had outperformed the New Zealand market since its separation from Tower Australia, it was the board's view that more shareholder value could be created," he said. "To this end the board is open to changing Tower's business structure to improve the value achieved for shareholders and is considering proposals including operational alliances and divestment of assets. "
Announcements about the propositions being investigated would be made if they represented realistic options for the company, he said. Talks with interested parties were expected to be completed in time for the annual meeting in February next year.
The shares last traded at $1.85 and have gained about 20 percent this year. Tower is rated a 'hold' based on a Reuters survey of five analysts.
No comments yet
Tower to return 'initial' $70M of capital from sale of life business
Tower shares fall to 2-month low as licensing requirements may weigh on capital returns
Tower's licensing talks with RBNZ may push up minimum solvency requirements
Tower names Hancock as new chief executive, replacing Flannagan
Tower posts first-half profit as asset sales reap gains of $51.4 mln
Fidelity Life acquires most of Tower's life insurance business
Flannagan to leave Tower after strategic review, asset sales
Tower FY profit jumps 67%, to return $120M to shareholders; shares jump
Tower sells medical insurance unit to nib for $102M
Stiassny joins Tower board as questions linger over strategy